The quest for efficiency – moving towards continuous processing
There are many challenges faced by the biopharmaceutical industry in order to develop and provide sufficient drugs to treat a growing and ageing population. This article discusses whether continuous processing provides the solution.
Today the pharmaceutical industry faces the challenge of an ageing population. Life expectancies across the developed world are increasing, thanks to growing wealth and better medicines. Germany’s average life expectancy has increased by more than 10 years since 19701 and in Latin America the increase is dramatic, with average life expectancy increasing by almost 20 years since 1960.2 One consequence of people living longer, combined with rising GDP, is that more patients are now living with chronic, complex conditions, such as heart disease, Alzheimer’s and type II diabetes. In the US, these are some of the most common causes of death, with millions more patients living with these diseases.3 Rates of diabetes in Mexico are increasing at three times the rate of population growth and almost 20 percent of public healthcare spending is on diabetes.4 In Japan, on average men suffer from at least one serious disease during their last nine years of life, while women suffer from at least one serious disease during their last 12 years of life.5